Toll-like receptors 3, 7, 8, and 9 in gastric cancer
|Author:||Eskuri, Maarit1; Kemi, Niko1; Helminen, Olli2;|
1Cancer and Translational Medicine Research Unit, Medical Research Center, University of Oulu and Oulu University Hospital, Oulu, Finland
2Surgery Research Unit, Medical Research Center, University of Oulu and Oulu University Hospital, Oulu, Finland
3Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
|Online Access:||PDF Full Text (PDF, 3 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2022122173024
John Wiley & Sons,
|Publish Date:|| 2022-12-21
Toll-like receptors (TLRs) have been shown to have anti-tumor, pro-tumor, or even dual effects in cancer, and are thus potential prognostic biomarkers and immunotherapeutic targets. The present study aimed to evaluate associations between endosomal TLRs, namely TLR3, TLR7, TLR8, and TLR9, expression and clinicopathological variables and survival in gastric cancer. A total of 564 gastric adenocarcinoma patients were included in this retrospective cohort study. Samples and clinicopathological data were retrieved and organized into tissue microarray blocks. Protein expressions were detected by immunohistochemical staining. The patients were divided into low expression and high expression groups by median values of expression. Cox regression provided hazard ratios (HR) with 95% confidence intervals (CI), adjusted for confounders. Patients with high nuclear TLR3 expression had significantly poorer 5-year survival than the low nuclear TLR3 expression group in the univariable analysis (crude HR 1.31, 95% CI 1.07–1.60). With radically resected patients, poor prognosis was also seen in the multivariable analysis (adjusted HR 1.38, 95% CI 1.08–1.77). Cytoplasmic TLR3, TLR7, TLR8, and TLR9 were not associated with 5-year survival. In conclusion, high nuclear TLR3 expression seems to have prognostic impact in gastric cancer, while TLR7, TLR8, and TLR9 do not.
|Pages:||92 - 99|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3126 Surgery, anesthesiology, intensive care, radiology
This study was supported by grants from The Finnish Medical Foundation (M.E), Finnish State Research Funding (O.H.), Orion Research Foundation (J.H.K.), Thelma Mäkikyrö Foundation (J.H.K. H.H), and Mary and Georg C. Ehrnroot Foundation (J.H.K. H.H), Päivikki and Sakari Sohlberg Foundation (J.H.K.), The Finnish Cancer Foundation (J.H.K.), The Finnish Cultural Foundation (H.H), Vieno and Alli Suorsa Healthcare Foundation (H.H) and Sigrid Juselius Foundation (J.H.K.). The study sponsors had no role in the design of the study, data collection, analysis, or interpretation of the results, writing of the manuscript, or the decision to submit the manuscript for publication.
© 2022 Scandinavian Societies for Pathology, Medical Microbiology and Immunology. This is the peer reviewed version of the following article: Eskuri, M., Kemi, N., Helminen, O., Huhta, H. and Kauppila, J.H. (2022), Toll-like receptors 3, 7, 8, and 9 in gastric cancer. APMIS, which has been published in final form at https://doi.org/10.1111/apm.13281. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. This article may not be enhanced, enriched or otherwise transformed into a derivative work, without express permission from Wiley or by statutory rights under applicable legislation. Copyright notices must not be removed, obscured or modified. The article must be linked to Wiley’s version of record on Wiley Online Library and any embedding, framing or otherwise making available the article or pages thereof by third parties from platforms, services and websites other than Wiley Online Library must be prohibited.